The Food and Drug Administration (FDA) has granted traditional approval for expanded uses of nivolumab, a human IgG4 monoclonal antibody, for certain adults with classic Hodgkin lymphoma, according to a recent announcement from Medscape Medical News. The agency’s decision extends beyond previously approved later-line treatments, now encompassing upfront use in combination with chemotherapy for classic […]
You can read the full story here: Nivolumab Approved for Later-Line Treatment in Adults | Medscape .